Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 9 Breast Neoplasms 8 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Osteosarcoma 2 Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Pathologic Complete Response 1 Neutropenia 1 Neoplasms 1 NSCLC 1 Myelosuppression 1 Limited Stage Small Cell Lung Cancer 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

Fluorouracil 497 Bevacizumab 476 Oxaliplatin 449 Leucovorin 440 Irinotecan 408 Cetuximab 317 Capecitabine 317 pembrolizumab 142 Folfox protocol 129 Panitumumab 117 regorafenib 105 Colonoscopy 88 Nivolumab 81 IFL protocol 81 Drug Therapy 77 trifluridine tipiracil drug combination 73 Radiotherapy 66 HMPL-013 65 Blood Specimen Collection 52 Gemcitabine 49 Specimen Handling 46 Neoadjuvant Therapy 45 Standard of Care 44 Magnetic Resonance Spectroscopy 43 Biopsy 43 Chemotherapy, Adjuvant 41 Trifluridine 40 atezolizumab 38 Surveys and Questionnaires 38 Cyclophosphamide 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Colorectal Neoplasms × trilaciclib × Clear all

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡